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Recently, we described the presence of highly sialylated N-linked glycans in the antigen-
binding fragment (Fab) of almost all anti-citrullinated protein antibody (ACPA) IgG molecules 
[1, 2]. These glycans could not be found on several other autoantibody systems analysed.  
Given the low affinity of ACPA [3], this observation raises the intriguing possibility that 
citrullinated antigen-specific B cells could be selected based on the presence of glycans in 
the variable domain, rather than on affinity for their cognate antigen. N-glycosylation requires 
the presence of specific consensus sequences in the amino acid backbone of proteins [4]. 
However, only few human germline Ig variable region genes encode for such sequences [5]. 
So far, we could identify several N-glycosylation sites in ACPA-IgG Fab-domains using mass 
spectrometry, but none of these were encoded in the germline sequence [1]. This suggests 
that the extensive presence of N-glycans in ACPA-IgG Fab-domains results from somatic 
mutations. Moreover, it indicates that the ACPA response matures under the influence of T-
cell help, presumably in germinal centres, and makes it conceivable that the introduction of 
N-glycosylation sites might be a crucial step by which tolerance checkpoints are breached. 
In this respect, it is relevant to note that ACPA are frequently present before the onset of 
clinical symptoms, and that recent epidemiological data indicate that the HLA-region is not a 
genetic risk factor for the development of ACPA, but associates strongly with ACPA-positive 
RA [6, 7]. Thus, the HLA-region, and thereby T-cells, contribute primarily to the maturation of 
the ACPA response rather than to its presence. If correct, additional glycosylation of the 
variable domain should be absent from ACPA-IgM. Here, we tested this hypothesis to gain 
insight in the biological processes underlying the extensive Fab-glycosylation of ACPA-IgG. 
ACPA-positive sera from patients with established RA were fractionated by size using gel-
filtration chromatography and tested for the presence of ACPA isotypes by ELISA [1]. 
Furthermore, ACPA were affinity-purified from synovial fluid and plasma followed by the 
heavy chain detection of ACPA isotypes by western blot [8]. Finally, the presence or 
absence of sialylated Fab-glycans on ACPA was tested by Sambucus nigra lectin (SNA) 
chromatography [9]. ACPA-IgG and -IgG1 consistently showed an increased molecular 
weight compared to non-citrulline specific IgG, consistent with the presence of Fab-glycans 
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(figure 1A, B [1]). In contrast, ACPA-IgM were identical in size compared to their non-
citrulline specific counterparts (figure 1B). ACPA-IgG Fab-glycans are highly sialylated [2] 
and therefore likely to interact with SNA. Consequently, ACPA-IgG could be strongly 
enriched upon SNA-purification, while ACPA-IgM remained in the SNA-negative fraction 
(figure 1C) indicating the absence of such glycan-species from ACPA-IgM. We conclude that 
the absence of a molecular “size-shift” for ACPA-IgM suggests that this ACPA isotype lacks 
additional glycosylation in the variable region. Unlike ACPA-IgG, ACPA-IgM seems to have 
an overall lower degree of sialylation independent of Fab glycosylation. These results are 
compatible with the notion that the acquisition of Fab-glycans in the variable domain of 
ACPA-IgG reflects a T-cell dependent process in the development of citrullinated antigen-
specific B cells in RA. In future studies, it will be crucial to understand the potential selective 




Figure 1. Molecular size analysis of ACPA-IgG and -IgM. (A) Presence of ACPA-IgG 
(black dots) and non-citrulline specific IgG (white dots) in gel-filtration chromatography 
fractions (lower fraction number indicates larger size; representative example of 7 donors). 
(B) Western blot of ACPA and non-citrulline specific control Ig isolated from patients (Pt) with 
established RA and stained for IgM, IgG and IgG1 (n=7). (C) Ratio of ACPA-IgM and -IgG (in 
AU) per non-citrulline specific IgM and IgG (in µg) in SNA-positive (SNA+) and –negative 
(SNA-) fractions (obtained using sera from n=8 additional donors; non-parametric Wilcoxon 
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